News

Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator to increase tear production in patients whose tear production is thought to be reduced due to ocular inflammation associated with dry eye syndrome.

Leading cataract surgeons discuss their comprehensive approach to IOL counseling, exploring how they bridge expectation gaps and tailor premium lens strategies to each patient's unique anatomy, goals, and lifestyle.

The company noted that this approval marks Celltrion's first Health Canada–approved biologic product in ophthalmology.

This is the first submission for approval under the exclusive license and commercialization agreement for South Korea that was signed between LENZ and Lotus.

HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.

The DRAGON trial was a 24-month pivotal phase 3 trial evaluating Tinlarebant in adolescent STGD1 patients.

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

To help with education and awareness, Prevent Blindness is providing free, expert-approved educational resources on GA.

Researchers analyze the DREAM study, revealing lid margin collarettes in dry eye patients and their surprising lack of progression over time.

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of patient-centered eye care.

Both therapeutics will leverage AGC Biologics’ BravoAAV suspension platform and use an innovative dual AAV vector approach, which splits the therapeutic gene into 2 halves.

The two meetings will be held concurrently from December 4-7 in Florence, Italy.

Discover cutting-edge retinal technologies and treatments at the FLORetina International Congress in Florence, featuring top exhibitors and expert presentations.

Phakic IOLs deliver a “wow” factor to refractive surgery patients, says Matteo Piovella, MD

Both therapeutics will leverage AGC Biologics’ BravoAAV suspension platform and use an innovative dual AAV vector approach, which splits the therapeutic gene into 2 halves.

Expanding accessibility in ophthalmic training does not require expensive, intricate programming, but reasonable, simple actions from senior clinicians

For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice.

HELIOS-3 is a phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

AAO 2025 revealed that true-color widefield imaging, AI-powered home OCT, and refined FAERS analyses are collectively transforming retinal diagnostics into a more precise, continuous, and safety-aware system.

Clinicians must assume responsibility for this common surgical concern